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Background: Cerebral palsy (CP) is a group of nonprogressive disorders of movement and posture caused by
abnormal development of, or damage to, motor control centers of the brain. A single nucleotide polymorphism
(SNP), rs1800795, in the promoter region of the interleukin-6 (IL6) gene has been implicated in the pathogenesis of
CP by mediating IL-6 protein levels in amniotic fluid and cord plasma and within brain lesions. This SNP has been
associated with other neurological, vascular, and malignant processes as well, often as part of a haplotype block.
Methods: To refine the regional genetic association with CP, we sequenced (Sanger) the IL6 gene and part of the
promoter region in 250 infants with CP and 305 controls.
Results: We identified a haplotype of 7 SNPs that includes rs1800795. In a recessive model of inheritance, the
variant haplotype conferred greater risk (OR = 4.3, CI = [2.0-10.1], p = 0.00007) than did the lone variant at rs1800795
(OR = 2.5, CI = [1.4-4.6], p = 0.002). The risk haplotype contains one SNP (rs2069845, CI = [1.2-4.3], OR = 2.3, p = 0.009)
that disrupts a methylation site.
Conclusions: The risk haplotype identified in this study overlaps with previously identified haplotypes that include
additional promoter SNPs. A risk haplotype at the IL6 gene likely confers risk to CP, and perhaps other diseases, via
a multi-factorial mechanism.
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Cerebral palsy (CP) is a group of nonprogressive motor
impairment syndromes caused by lesions of the brain
arising early in development. The motor disorders of CP
are often accompanied by disturbances of sensation, per-
ception, cognition, communication, and behavior; by epi-
lepsy; and by secondary musculoskeletal problems [1]. A
number of risk factors for the condition have been iden-
tified, including preterm birth, intrauterine infection,
intrauterine growth restriction, perinatal stroke, and a
sibling with CP [2-7]. How the fetus responds in the
presence of these risk factors is influenced by its genetic
makeup, with some genotypes creating susceptibility to* Correspondence: pouya.khankhanian@ucsf.edu; WuY@neuropeds.ucsf.edu
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distribution, and reproduction in any mediumcerebral damage [8,9]. Several rare genetic variants that
cause Mendelian forms of CP have been described [10];
however, these do not account for the vast majority of
CP cases.
Interleukin-6 (IL6) is a cell signaling molecule that has
been associated with over 20 diseases, including inflam-
matory, neurological, vascular, and malignant processes
(Additional file 1: Table S1). The most studied single
nucleotide polymorphism (SNP) in the IL6 gene is
rs1800795 (−174G > C). This SNP lies within the pro-
moter region and the C allele has been associated
with either increases or decreases inIL6 levels in several
tissues [11-14].
Both the IL-6 gene and IL-6 protein levels have been
linked with increased risk of CP. Within the IL6 gene, the
C allele at rs1800795 has been associated with increased
risk of CP in large population studies [15-17]. Elevated
cerebrospinal fluid IL-6levels have been associated with
worse neurologic outcomes following hypoxic-ischemicentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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plasma and amniotic fluid and within brain lesions have
been associated with periventricular leukomalacia, a major
risk factor for CP in preterm infants [19-22]. Higher cord
blood IL-6 protein levels also predict cerebral lesions on
MRI in preterm infants [23].
To our knowledge, no IL6 sequencing or haplotype
studies have been performed to further evaluate the rela-
tionship between IL6 genotype and CP. Therefore, we
performed Sanger sequencing of the IL6 gene in a nested
case control study of CP among term infants to identi-
fyIL6 haplotypes and mutations that predispose individ-
uals to high risk of CP.
Methods
Study participants and samples
We studied 250 infants with CP and 305 randomly se-
lected control infants born at > = 36 weeks gestation
within the Kaiser Permanente Medical Care Program
(KPMCP) during1991-2002, as previously described [17].
Briefly, we searched KPMCP records for physician diag-
noses of “cerebral palsy,” “paresis,” “gait abnormality,” or
“cerebral degeneration.” A single child neurologist
(author YWW) reviewed medical records to confirm the
diagnosis of CP. We defined CP as a non-progressive
congenital motor dysfunction with examination findings
of increased tone (spasticity, rigidity, dystonia) or chor-
eoathetosis. Children with hypotonia, ataxia, myopathy,
neural tube defect, genetic syndrome, and chromosomal
anomaly were excluded. Infants with CP whose blood
samples were unavailable for study (47), whose blood
samples were taken after having received a blood transfu-
sion (5), or whose blood samples were mislabeled (1), were
excluded. A random sample of 305 infants from the study
population with available blood samples comprised the
control group of this study. All blood samples for DNA
purification came from heel-stick dried blood collected in
the neonatal period for purposes of newborn screening as
part of the California Newborn Screening Program (NBS),
unused portions of blood spots are stored in archives at
the California Department of Public Health with standard
procedure to avoid cross contamination [17]. For this
study, punch biopsies of unused portions of blood spots
were used for DNA extraction. We received a waiver of
consent from the state of California IRB and the IRBs of
the individual institutions. To prevent cross contam-
ination between biopsies, the stainless punch was soaked
in ethanol, then the ethanol-soaked punch was placed over
open flame to burn off residual ethanol and DNA. DNA
extraction and amplification was performed using QIAamp
96 DNA kits supplied by Qiagen (Chatsworth, CA), and
RepliPHI Phi 29 Reagent Sets (Epicentre Technologies,
Madison, WI) as previously described [17]. Ethnicity data
was determined from chart review, using pre-definedcategories within the KPMCP system: African American
(26/22 =Cases/Controls), Asian (26/47), Hispanic (48/51),
white (138/163), and others including mixed and unknown
(12/22). Study procedures were approved by the institu-
tional review boards at KPMCP, University of California
San Francisco, and the California Committee for Protec-
tion of Human Subjects.
Sanger sequencing
A combination of long and short amplicons was used to
sequence 5000 base pairs covering the IL6 gene starting
300 bases upstream from the transcription start site. In
total, 9 long amplicons and49 short amplicons were gener-
ated and later sequenced using standard di-deoxy termin-
ator chemistry and capillary electrophoresis technology in
an ABI 3730XL instrument (Applied Biosystems, Foster
City, CA). Calls were made using Sequencher software
(Gene Codes Corporation, Ann Arbor, MI). Genotype calls
at important loci of interest were confirmed by manual
calls made by two independent operators looking at peaks
on an electropherogram using standard procedure. Any
discrepant calls were labeled missing (Additional file 2:
Table S2). SNP functionality was assessed using the poly-
phen2 database [24] and the UCSC genome browser [25].
Hardy-Weinberg equilibrium was measured in controls
from each population. In accordance with previous stud-
ies, the zero position is defined as the start of the tran-
scribed portion of the gene, with numbers increasing in
the direction of transcription, such that the +174 position
aligns with rs1800795. Calls were made on the tran-
scribed strand.
Analysis
Linkage disequilibrium (LD) between the rs1800795 SNP
and neighboring SNPs has been described in at least 9
studies, as detailed in Additional file 1: Table S1. The
haplotype block of interest is defined differently in each of
these studies, making it impossible to define a single con-
sensus haplotype block of interest containing rs1800795.
To resolve ambiguity regarding haplotype block defin-
ition in IL6, particularly the block containing rs1800795
(Additional file 1: Table S1), we began by investigating
haplotype structure in healthy controls from each popu-
lation. After reproducing the association between CP and
rs1800795, we performed focused tests for association
between CP and the haplotype containing rs1800795,
followed by tests for association between CP and likely
functional variants. Finally, we performed an unbiased
search for association between CP and all other variants
and haplotype blocks. For all association testing, the four
populations were pooled; for association testing for com-
mon variants, population subgroup analysis was also per-
formed. The R base package was used for statistical
analysis except as stated. To elucidate the effect of known
Figure 1 Experimental design. Experimental workflow: sample sizes,
number and type of variants identified, and analyses performed.
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tests were performed. The effect of a single copy of
variant allele was compared to wildtype using a Fisher’s
exact test on the 2 × 2 table (heterozygote vs. homozygote
wildtype), and the effect of two copies of the variant allele
was measured using a Fisher’s exact test on a 2 × 2 table
(homozygote variant vs. homozygote wildtype). This two-
part test has the ability to capture a completely dominant
model of inheritance (where both tests will be positive), a
completely recessive model of inheritance (where only the
second test is positive), a pure dose model of inheritance
(where the effect size of the first test will be half the effect
size of the second test), or any other model within the
spectrum. Screening for other variants in IL6 that have
not been previously described was performed as follows.
For common variants, a “genotypic” test was performed
on the 2 × 3 table of genotype versus case status, as well
as an allele frequency test both using Plink software. For
rare variants, the allele frequency test was performed,
but the “genotypic” test was replaced by a “dominant”
test on a 2 × 2 table of genotypes ((homozygous variant +
heterozygote) vs. wildtype). Logistic regression was also
performed, yielded similar results, and is not shown.
Haplotype definition
Variants were classified into haplotype blocks in each of
the four large populations as follows. Pair-wise linkage
disequilibrium between variants was calculated using r2.
Variants were re-ordered by unsupervised hierarchical
clustering using 1-r2 for distance and the Ward [26] algo-
rithm of agglomeration. Branches of the dendrogram de-
fined groups of non-sequential SNPs were grouped into
haplotype blocks with intra-haplotype r2 > 0.3 (Additional
file 3: Figure S1). In most cases, long sequencing reads
provided haplotype (phased genotype) information for any
given individual. When phasing could not be determined
by direct sequencing results, a maximum likelihood model
was used to infer haplotypes. An individual’s genotype at
the haplotype block is defined on each chromosome. A
haplotype is called wildtype if all SNPs called within the
haplotype are wildtype and at least half of the SNPs within
the haplotype are called. A haplotype is called variant if all
SNPs within the haplotype are variant and at least half
of the SNPs within the haplotype are called. Hardy-
Weinberg equilibrium for the haplotype was measured in
controls from each population.
Results and discussion
Descriptive statistics: variants and haplotypes called
In total, 61 variable loci were identified in the dataset
(Figure 1, Additional file 4: Table S3). Fifteen of these were
common polymorphisms in the population (defined by
minor allele frequency (MAF) > 5% in controls), including
previously described SNP rs1800795 (−174G > C) [17].Uncommon variants (allele frequency less than 5%) in-
cluded two frameshift mutations. One frameshift mutation
at position 316 likely disrupts gene function by generating
a stop codon near the 5′ end of the first exon of the gene,
effectively removing nearly all protein domains. The other
frameshift mutation at position 2494 is unlikely to be
damaging because it occurs at the 3' end of the last exon
of some transcript variants and does not affect other tran-
script variants.
Variants were grouped into haplotype blocks in each
population using r2 as a measure of linkage disequilib-
rium, using Ward hierarchical clustering to re-order SNPs.
The greatest linkage disequilibrium (LD) was seen in
whites, followed closely by Hispanics and Asians, with
African Americans showing the least LD (Additional
file 3: Figure S1). In white controls, five haplotype blocks
were identified with intra-block r2 > 0.3 and the inter-block
r2 < 0.3 (Additional file 3: Figure S1). These five haplotype
blocks included 18 of 61 variants. The rs1800795 SNP
was included in a 7-SNP haplotype block: rs1800795
(−174), rs2069832 (615), rs2069833 (846), rs1474348
(1090), rs1474347 (1306), rs1554606 (1889), and rs2069845
(3331). In Hispanic controls, three haplotype blocks were
identified, which included 13 variants. These blocks were
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white controls. This includes the same 7-SNP haplotype
block for rs1800795. In Asian controls, three haplotype
blocks were identified including 11 variants. One of these
blocks was again the same 7-SNP haplotype of rs1800795.
Another block was identical to one found in Hispanics and
whites. The third block found in Asians was a smaller ver-
sion of the other block found in Hispanics and whites.
Finally, in African Americans, five blocks were identified
containing 12 SNPs. This time the rs1800795 SNP was part
of a smaller 4-SNP haplotype, a subset of the 7-SNP haplo-
type found in the other three populations. The other four
blocks found in African Americans included one block that
was identified in all populations (1401 and 1431) and three
novel blocks.
The 7-SNP block, which includes rs1800795 and was
identified in whites, Hispanics, and Asians, includes an
intronic SNP rs20698455 that disrupts a CpG methylation
[27] along with 5 other intronic SNPs. The smaller 4-SNP
block of rs1800795 identified in African Americans is a
subset of the 7-SNP block but does not include the
rs20698455 SNP. Overlap between the7-SNP haplotype
and previously reported haplotypes is shown in red text in
Additional file 1: Table S1.
The rs1800795 haplotype
The rs1800795 SNP was identified as part of a 7-SNP
haplotype block in whites, Hispanics, and Asians, and as
part of a smaller 4-SNP block in African Americans.
Among control infants, the variant haplotype allele was
more common among whites (26% and 27% for the 7-SNP
and 4-SNP haplotypes respectively) than among Hispanics
(10% and 13%), Asians (7% and 7%), or African Americans
(4% and 5%). There was no evidence of Hardy-Weinberg
disequilibrium for either the haplotypes or for any of the
SNPs in controls of each population.
The association between the 7-SNP haplotype and CP
was stronger than the association seen between any indi-
vidual SNP and CP, or between the 4-SNP haplotype and
CP. Five of seven SNPs in this block showed significant
association with CP with a recessive pattern of inherit-
ance (Table 1). The odds ratio (OR) of association for
homozygote versus wildtype at individual SNPs was at
most 2.7. However, the OR for homozygotes for the vari-
ant at the full 7-SNP haplotype block variant was 4.3
(95% confidence interval (CI) = [2.0-10.1], Fisher exact
test p = 0.00007, Bonferroni corrected p = 0.0004). The
OR for homozygotes at the smaller 4-SNP haplotype was
3.0 (CI = [1.5-6.0], p = 0.0007, corrected p = 0.004). There
was no evidence of increased risk for heterozygous car-
riers of any of these variant SNPs or for heterozygous
carriers of the variant 4-SNP or 7-SNP haplotype.
Population subgroup analysis of the 7-SNP haplotype
block revealed a significant odds ratio for homozygouswhite (OR = 3.18, CI = [1.3-8.4], one-sided p = 0.007) and
Hispanic infants (OR = 8.02, CI = [0.9-400], one-sided
p = 0.045), with no evidence of increased risk for heterozy-
gotes (Figure 2). Only two African American infants and
one Asian infant were homozygotes; all three had CP.
Population subgroup analysis of the 4-SNP haplotype
block showed a similar pattern across populations, though
effect sizes were proportionally reduced in relation to the
7-SNP haplotype (not shown). Subgroup analysis revealed
significant odds ratios in males (OR = 4.6, CI = [1.6-15],
one-sided p = 0.0006) and females (OR = 3.04, CI = [0.9-
10.9], one-sided p = 0.03), and across body weights (there
were no case or control homozygote variants with birth
weight less than 2500 g).
The frameshift mutation
As described above, one of the rare variants identified
resulted in a frameshift at position 316 within the first exon
and caused early protein truncation, thus warranting a fo-
cused analysis of this variant. Within this case–control
dataset, the frameshift allele was found in four Asian in-
fants (allele frequency = 2.5%), two Hispanic infants (allele
frequency = 1%), three white infants (allele frequency =
0.6%), and one infant of other ethnicity. The lone homozy-
gote was white. In total, eight of ten carriers of the frame-
shift allele were infants with CP (OR = 4.53, CI = [0.9-44],
p-value = 0.053) including the lone homozygote carrier.
Clinical characteristics of the eight infant frameshift car-
riers are shown in Table 2. Of note, three of eight carrier
infants had perinatal stroke (versus 20.2% of non-carriers),
including the lone homozygote carrier, though this result
was not statistically significant. To control for possible con-
founding effects, individuals homozygous for the variant
haplotype allele described above were excluded in the ana-
lysis of the frameshift mutation.
Analysis of other variants
Finally, we carried out an unbiased analysis of the fifteen
common variants identified in this population. When cor-
rected for multiple hypotheses testing using the method of
Bonferroni, we found no evidence of association (p > 0.05)
with CP for any variants other than those described above.
This was true for the entire dataset (Additional file 5: Table
S4) and also for each population subgroup (not shown). Of
the 46 rare variants, 20 were found in more than one indi-
vidual. Unbiased analysis of these 20 rare variants using a
dominant model revealed no significant association after
correction for multiple testing (Additional file 6: Table S5).
We deemed this analysis underpowered due to the small
sample size and the large number of hypotheses tested.
Conclusions
In this study, we found strong association of CP with
an extended 7-SNP haplotype containing the functional
Figure 2 Subgroup analysis. Mean (boxes) and 95% confidence intervals (lines) for carriers of the variant haplotype by ethnicity, birth weight,
and sex. Increased risk for homozygote carriers reached statistical significance in whites, Hispanics (one-sided only), males, and females (one-sided
only). There was no risk associated with heterozygote carriers in any subgroup.
Table 1 Genetic association with CP
rs ID Position Homozygote vs. wt OR 95% CI P Bonf
rs1800795 −174 C/C versus G/G 2.5 1.4-4.6 0.002 0.03 Promoter
rs2069832 615 A/A versus G/G 2.7 1.4-5.5 0.001 0.02 Intron
rs2069833 846 C/C versus T/T 2.4 1.3-4.6 0.004 0.05 Intron
rs1474348 1090 C/C versus G/G 1.5 0.6-3.6 0.33 1 Intron
rs1474347 1306 C/C versus A/A 1.8 0.8-3.6 0.1 0.9 Intron
rs1554606 1889 T/T versus G/G 2.5 1.5-4.5 0.0005 0.007 Intron
rs2069845 3331 G/G versus A/A 2.3 1.2-4.3 0.009 0.09 CpG site*
4-SNP haplotype blocka 3.0 1.5-6.0 0.0007 0.004
7-SNP haplotype blockb 4.3 2.0-10.1 0.00007 0.0004
rs ID Position Homozygote vs. wt OR 95% CI P Bonf
rs1800795 −174 C/G versus G/G 1.3 0.8-2.0 0.33 1 Promoter
rs2069832 615 A/G versus G/G 1.3 0.8-2.0 0.28 1 Intron
rs2069833 846 C/T versus T/T 1.4 0.9-2.1 0.19 1 Intron
rs1474348 1090 C/G versus G/G 1 0.6-1.7 1 1 Intron
rs1474347 1306 C/A versus A/A 0.7 0.3-1.8 0.5 1 Intron
rs1554606 1889 T/G versus G/G 1.1 0.8-1.7 0.5 1 Intron
rs2069845 3331 G/A versus A/A 1 0.5-2.3 1 1 CpG site*
4-SNP haplotype blocka 1 0.6-1.6 1 1
7-SNP haplotype blockb 1 0.5-1.7 0.9 1
*[27]; wt = wildtype; OR = odds ratio; CI = confidence interval; Bonf = Bonferroni correction for multiple hypothesis testing. For SNPs, correction was done for 14
total common SNPs tested.
aThe 4-SNP block includes rs1800795, rs2069832, rs2069833, rs1474348. It was one of five haplotypes identified in African American controls. Bonferroni correction
for five hypotheses tested.
bThe 7-SNP block includes all SNPs listed in table. It was one of five haplotypes identified in white controls, one of three in Hispanic controls, and one of three in
Asian controls. Bonferroni correction for 5 hypotheses tested.
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Neuroimaging Perinatal Stroke 3
(6CT, 1MRI) Global injury / volume loss 2
No abnormalities 2
No imaging 1
Perinatal Emergent Caesarian 4
Complications Preeclampsia 1
Maternal temp < 100.5 1
Meconium 1
Neonatal seizures 2
*Moderate/severe = impaired function of most affected limb;
mild = unimpaired function.
^All patients were diagnosed by a pediatric neurologist. Spasticity was present
in all 8 patients; none had extra-pyramidal signs.
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inheritance. We observed greater risk for homozygotes
at the entire haplotype than for homozygotes at a smaller
4-SNP haplotype identified in African Americans, or for
homozygotes at any individual locus. This suggests that
there may be more than one functional locus within
the 7-SNP haplotype, and that at least one functional locus
may be outside of the smaller 4-SNP haplotype. In addition
to the promoter function ofrs1800795 that is within the
smaller 4-SNP haplotype, disruption of a methylation site
at position rs2069845 [27] could be part of the mechanism
conferring additional risk.
The variant rs1800795 has been implicated in various
neurological, vascular, and malignant processes (Additional
file 7). In these disease processes, it has often been impli-
cated as part of a haplotype with (or implicated simultan-
eously with) other SNPs including many of the SNPs
identified in this study (Additional file 1: Table S1). Two
SNPs which have been previously found on haplotypes
with rs1800795 include a rare missense SNP rs13306435
(4220 T >A) [28] and an intron SNP rs2069840 [29]; nei-
ther showed evidence of association with CP in this study,
although analysis of the rare missense SNP was likely
underpowered. Other SNPs that have been previously
found on haplotypes with rs1800795 but were outside the
genotyping bounds of this study include possibly functional
promoter SNPs(rs1800796 and rs1800797) [13] and less
likely functional SNPs from the 5′ untranslated region
(rs12700386, rs7802307, rs7802308, rs2069827) and the 3′
untranslated region (rs11766273, rs2069861, rs1818879). Astudy published after our analysis was complete [30] sug-
gests that rs1800796-rs2069837 may be associated with
risk in a subset of CP patients: Chinese males with spastic
paraplegia. We found no association between rs2069837
and CP. However, our analysis was underpowered as this
variant is rare in whites, Hispanics, and African Americans.
The effect of the rs1800795 variant or the entire haplotype
variant on the expression level of IL6 is not fully under-
stood, with evidence for the CC genotype being associated
with high or low expression in different tissues [11-14].
We found a trend for association of CP with a likely
damaging rare frameshift mutation at position 316. Due
to the rarity of this allele (frequency ~ 1%), a larger study
would be needed to confirm this finding. Larger studies
or meta-analyses can assess potential association with
the other uncommon variants. However, such variants
would be uncommon, even in CP patients, and therefore
explain a small fraction of population risk.
There are a variety of common approaches to haplotype
definition which have been used to describe IL6. Among
other common methods (Additional file 1: Table S1), the
method presented here is appealing because it achieves
unequivocal haplotype boundaries (i.e. intra-haplotype
r2 > 0.3, inter-haplotype r2 < 0.3 for any pair-wise com-
parison of SNPs). This method is not impaired by con-
tiguous SNP inclusion criteria (i.e. it allows defined
haplotypes to include non-contiguous SNPs), an impair-
ment which would have made the discovery of this haplo-
type impossible in a sequencing dataset due to the high
number of variants found. This method minimizes prob-
ability of winner’s curse by reducing the number of hy-
potheses tested to less than n (where n is the number of
SNPs found), while other methods increase the number
of tests to several fold higher than n. Other haplotype
methods that seek independence rather than correlation
can also achieve the same criteria, see for example [31].
A combination of both approaches (i.e. seeking an effect
of a second haplotype while conditioning on the lead
haplotype) is also possible, but did not yield significant
results and was not shown. The method used in this
current study is more likely to prove useful in a low-
quality (high missing-ness) dataset where increasing
signal-to-noise (by selecting multiple correlated mea-
sures) is more important.
Previous genetic studies of IL6 in CP have been lim-
ited to a handful of SNPs; sequencing presented several
advantages. We have been able to fully describe the
haplotype block of rs1800795 (to within the bounds of
genotyping). Sequencing has also revealed a frameshift
variant that causes early protein termination and absence
of the four largest protein domains. Finally, sequencing al-
lows us to rule out any other high-risk common variants
(other than those discussed) within the boundaries of
genotyping. A limitation of this study is the boundaries of
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of the mechanism conferring additional risk to CP. An-
other limitation was the low quality of the sequencing due
in large part to low quantity of blood available in each
sample, as this study “recycled” unused portions of blood
samples after they had been used for routine newborn
screening. To address this, we used manual calls made by
2 independent operators to confirm significant findings,
discarding all calls that were not concordant. Thus, we
sacrificed call rate for accuracy. Another limitation is the
lack of confirmation of genotyping and lack of external
replication, although it is reassuring that the main haplo-
type findings were significant independently in whites and
Hispanics, as well as in males and females. The haplotype
identified in this study, plus additional SNPs in the pro-
moter region, may play a role in other diseases. Targeted
genotyping of all haplotype SNPs in CP and other diseases
using independent replication populations would be of
interest. A genome-wide association study of CP may re-
veal additional genetic loci which predispose to this het-
erogeneous group of diseases.
Additional files
Additional file 1: Table S1. rs1800795 haplotype. A survey of published
haplotype analyses of rs1800795.
Additional file 2: Table S2. SNP-level missingness. Genotypes were
labeled missing when consensus could not be reached by independent
operators making genotype calls.
Additional file 3: Figure S1. A - Linkage Disequilibrium. Haplotype blocks
of r-squared in white controls. B - Linkage Disequilibrium. Haplotype blocks of
r-squared in Hispanic controls. C - Linkage Disequilibrium. Haplotype blocks
of r-squared in African American controls. D - Linkage Disequilibrium.
Haplotype blocks of r-squared in Asian controls.
Additional file 4: Table S3. Summary of variants identified. A total of
61 variants were observed in all samples including cases and controls.
Additional file 5: Table S4. Unbiased analysis of common variants. No
evidence for association outside of the rs1800795 haplotype block after
correction for multiple hypothesis testing.
Additional file 6: Table S5. Unbiased analysis of common variants. No
evidence for association after correction for multiple hypothesis testing.
Additional file 7: rs1800795 and human disease. A survey of
published studies linking this SNP to human disease in the last decade.
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